Understregning af, at forholdet mellem risikoen og fordelene ved behandling af trombocytopeni hos ikke- ITP- patientpopulationer er ikke afklaret.
Reiteration that the risk-benefit for the treatment of thrombocytopenia in non ITP patient populations has not been established.